Ubs Group Ag Eagle Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 480 shares of EGRX stock, worth $268. This represents 0.0% of its overall portfolio holdings.

Number of Shares

480

Previous 482 0.41%

Holding current value

$268

Previous $2,000 50.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.71 - $6.07 $7 - $12	-2 Reduced 0.41%	480 $1,000
Q2 2024 Aug 13, 2024	SELL	$3.34 - $5.6 $39,101 - $65,559	-11,707 Reduced 96.05%	482 $2,000
Q1 2024 May 13, 2024	BUY	$4.26 - $6.51 $16,264 - $24,855	3,818 Added 45.61%	12,189 $63,000
Q4 2023 Feb 09, 2024	SELL	$4.63 - $15.21 $43,989 - $144,510	-9,501 Reduced 53.16%	8,371 $43,000
Q3 2023 Nov 09, 2023	SELL	$15.21 - $22.88 $295,226 - $444,100	-19,410 Reduced 52.06%	17,872 $281,000
Q2 2023 Aug 11, 2023	BUY	$17.74 - $31.87 $471,227 - $846,562	26,563 Added 247.81%	37,282 $724,000
Q1 2023 May 12, 2023	SELL	$25.06 - $34.09 $876,197 - $1.19 Million	-34,964 Reduced 76.54%	10,719 $304,000
Q4 2022 Feb 08, 2023	BUY	$24.98 - $39.77 $893,784 - $1.42 Million	35,780 Added 361.3%	45,683 $1.34 Million
Q3 2022 Nov 10, 2022	BUY	$26.42 - $47.12 $36,670 - $65,402	1,388 Added 16.3%	9,903 $261,000
Q2 2022 Aug 10, 2022	SELL	$41.26 - $51.35 $765,331 - $952,491	-18,549 Reduced 68.54%	8,515 $378,000
Q1 2022 May 16, 2022	SELL	$44.58 - $52.6 $296,367 - $349,684	-6,648 Reduced 19.72%	27,064 $1.34 Million
Q4 2021 Feb 14, 2022	BUY	$45.82 - $56.9 $481,476 - $597,905	10,508 Added 45.29%	33,712 $1.72 Million
Q3 2021 Nov 15, 2021	BUY	$43.79 - $55.78 $661,360 - $842,445	15,103 Added 186.43%	23,204 $1.3 Million
Q2 2021 Aug 13, 2021	SELL	$36.86 - $44.5 $485,741 - $586,421	-13,178 Reduced 61.93%	8,101 $347,000
Q1 2021 May 12, 2021	BUY	$40.32 - $50.97 $855,953 - $1.08 Million	21,229 Added 42458.0%	21,279 $888,000
Q2 2020 Jul 31, 2020	SELL	$43.24 - $55.02 $148,269 - $188,663	-3,429 Reduced 98.56%	50 $2,000
Q1 2020 May 01, 2020	SELL	$34.37 - $60.07 $75,579 - $132,093	-2,199 Reduced 38.73%	3,479 $160,000
Q4 2019 Feb 14, 2020	SELL	$54.32 - $64.31 $1.13 Million - $1.34 Million	-20,760 Reduced 78.52%	5,678 $342,000
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $824,150 - $928,310	-15,477 Reduced 36.92%	26,438 $1.5 Million
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $1.8 Million - $2.26 Million	38,608 Added 1167.46%	41,915 $2.33 Million
Q1 2019 May 14, 2019	SELL	$38.66 - $51.82 $3.01 Million - $4.04 Million	-77,885 Reduced 95.93%	3,307 $167,000
Q4 2018 Feb 14, 2019	BUY	$36.72 - $67.73 $2.55 Million - $4.7 Million	69,367 Added 586.61%	81,192 $3.27 Million
Q3 2018 Nov 14, 2018	BUY	$66.65 - $83.86 $756,210 - $951,475	11,346 Added 2368.68%	11,825 $820,000
Q2 2018 Aug 14, 2018	SELL	$51.25 - $76.62 $2.43 Million - $3.64 Million	-47,501 Reduced 99.0%	479 $36,000
Q1 2018 May 15, 2018	BUY	$52.16 - $66.86 $1.96 Million - $2.51 Million	37,597 Added 362.1%	47,980 $2.53 Million
Q4 2017 Feb 14, 2018	SELL	$49.6 - $60.87 $852,425 - $1.05 Million	-17,186 Reduced 62.34%	10,383 $554,000
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $648,670 - $839,849	13,914 Added 101.9%	27,569 $1.64 Million
Q2 2017 Aug 14, 2017	BUY	N/A	12,318 Added 921.32%	13,655 $1.08 Million
Q1 2017 Nov 14, 2017	BUY	N/A	1,337	1,337 $111,000

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.29M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account